Measurement of Thromboxane Production in Vivo: Metabolic and Analytical Aspects
In studies aiming at establishing a role for thromboxanes in various physiological or pathological conditions, it is often desirable to measure the endogenous thromboxane production. Since TXA2 is difficult to measure as such, a common approach in such studies is to monitor its stable hydrolysis product, TXB2, instead, and to compare obtained TXB2 levels in, for example, plasma samples in patient and control groups. Numerous such studies have been published to date; however, even the so called “basal” TXB2 levels reported therein vary widely. Not infrequently, “basal” TXB2 levels were found to be around 100–200 pg/ml plasma or even higher, however, others claim to find values below 15, 10 or even 2 pg/ml (e.g., refs. 1–6). It is difficult to explain such differences between studies where identical assay methods have been used (for example a commercially available TXB2 radioimmunoassay); that is, if the obtained data really reflect the endogenous situation.
KeywordsPlatelet Rich Plasma Dioic Acid Thromboxane Production Unlabeled Ligand Major Urinary Metabolite
Unable to display preview. Download preview PDF.
- 6.K. Andrassy, J. Koderisch, B. Kern and E. Ritz, Does arachidonic acid interfere with measurements of thromboxane B2? Thromb. Haemost., 47: 185 (1982).Google Scholar
- 9.Y. Hayashi, N. Ueda, K. Yokota, et al., Enzyme immunoassay of thromboxane B2, Biochim. Biophys. Acta, 750: 322 (1983).Google Scholar
- 11.J. Svensson, M. Hamberg and B. Samuelsson, On the formation and effects of thromboxane A2 in human platelets, Acta Physiol. Scand., 98: 285 (1976).Google Scholar
- 12.C. Patrono, This symposium.Google Scholar
- 13.D.S. McCann, J. Tokarsky and R.P. Sorkin, Radioimmunoassay for plasma thromboxane B2, Clin. Chem., 27: 1417 (1981).Google Scholar
- 14.C. Patrono, G. Ciabattoni, E. Pinca, F. Pugliese, G. Castrucci, A. DeSalvo, M.A. Satta and B.A. Peskar, Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects, Thromb. Res., 17: 317 (1980).Google Scholar
- 15.M. Thorngren, S. Shafi and G.V.R. Born, Thromboxane A2 in skin bleeding-time blood and in clotted venous blood before and after administraiton of acetylsalicylic acid, Lancet, i: 1075 (1983).Google Scholar
- 16.E. Granström, H. Kindahl and M.-L. Swahn, Profiles of prostaglandin metabolites in the human circulation: Identification of late-appearing long lived products, Biochim. Biophys. Acta, 713: 46 (1982).Google Scholar
- 17.E. Granström and H. Kindahl, Species differences in circulating prostaglandin metabolites: Relevance for the assay of prostaglandin release, Biochim. Biophys. Acta, 713: 555 (1982).Google Scholar
- 21.P. Westlund, M. Kumlin and E. Granström, Metabolism of thromboxane B2 in the rabbit: Urinary and blood metabolic profile, to be published.Google Scholar
- 22.P. Westlund, A. Nordenström, M. Kumlin and E. Granström, Circulating metabolites of thromboxane B2 in the human, to be published.Google Scholar
- 25.C. Patrono, G. Ciabattoni, P. Patrignani, P. Filabozzi, E. Pinca, M.A. Satta, D. Van Dorne, G.A. Cinotti, F. Pugliese, A. Perucci, and B.M. Simonetti, Evidence for a renal origin of urinary thromboxane B2 in health and disease, Adv. Prostaglandin Thromboxane Res., 11: 493 (1983).Google Scholar